Jeremy R. Jackson

ORCID: 0009-0006-5980-6799
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neuroblastoma Research and Treatments
  • Cancer, Hypoxia, and Metabolism
  • Cancer therapeutics and mechanisms
  • Immune cells in cancer
  • Lung Cancer Research Studies
  • Glioma Diagnosis and Treatment
  • Neuroendocrine Tumor Research Advances
  • Intestinal Malrotation and Obstruction Disorders
  • Virus-based gene therapy research
  • Sports injuries and prevention
  • Esophageal and GI Pathology
  • Dysphagia Assessment and Management
  • Cancer-related Molecular Pathways
  • Cardiac, Anesthesia and Surgical Outcomes
  • Xenotransplantation and immune response
  • Shoulder Injury and Treatment
  • Muscle activation and electromyography studies
  • Cancer-related molecular mechanisms research
  • Cardiovascular Effects of Exercise
  • Body Composition Measurement Techniques
  • Gastrointestinal disorders and treatments
  • Appendicitis Diagnosis and Management
  • Pediatric Hepatobiliary Diseases and Treatments
  • Congenital gastrointestinal and neural anomalies
  • Tracheal and airway disorders

Sports Medicine Australia
2024

Children's Hospital of Los Angeles
2007-2019

University of Southern California
2007-2016

Immunotherapy of high-risk neuroblastoma using the anti-GD2 antibody dinutuximab induces antibody-dependent cell-mediated cytotoxicity (ADCC). Galunisertib, an inhibitor TGFβR1, was examined for its ability to enhance efficacy in combination with human ex vivo activated NK (aNK) cells against neuroblastoma.TGFB1 and TGFBR1 mRNA expression determined 249 primary tumors by microarray analysis. The galunisertib inhibit SMAD activity induced patient blood bone marrow plasmas tested. impact on...

10.1158/1078-0432.ccr-16-1743 article EN cc-by Clinical Cancer Research 2016-10-11

Neuroblastoma is an aggressive pediatric malignancy which >98% p53 wild-type at diagnosis. As a primary repressor of activity and part p53-activated negative feedback loop, targeting mouse double minute 2 homolog (MDM2) attractive therapeutic approach to reactivation p53. Since development the first selective MDM2 inhibitor, Nutlin-3a, newer compounds have been developed for increased potency improved bioavailability. Herein, we sought determine efficacy specificity second-generation RG7388,...

10.1038/cddiscovery.2015.26 article EN cc-by Cell Death Discovery 2015-08-24

Prospective cohort.To explore the association between preseason assessments of (1) isometric hip adductor and abductor strength using a novel field test (2) Copenhagen Hip Groin Outcome Score (HAGOS) subsequent hip/groin injury in male professional soccer players.In total, 204 elite players from 10 A-League English Football League Championship clubs underwent completed HAGOS 2017-2018 preseason. All injuries were reported by team medical staff. Data reduction was conducted...

10.2519/jospt.2020.9022 article EN Journal of Orthopaedic and Sports Physical Therapy 2019-09-18

Immunotherapy of neuroblastoma that remains after myeloablative chemotherapy with anti-GD2 antibody dinutuximab has increased the two-year event-free and overall survival high-risk patients; however, 40% patients develop recurrent disease during or this treatment. To determine potential such antibody-based immunotherapy earlier in treatment, a mouse model was developed which surgical resection primary tumor followed by therapy residual combined ex vivo-activated human natural killer (aNK)...

10.1158/1078-0432.ccr-18-1317 article EN Clinical Cancer Research 2018-09-19

Tumor‐associated macrophages can promote growth of cancers. In neuroblastoma, tumor‐associated have greater frequency in metastatic versus loco‐regional tumors, and higher expression genes associated with helps to predict poor prognosis the 60% high‐risk patients who MYCN ‐non‐amplified disease. The contribution cytotoxic T‐lymphocytes anti‐neuroblastoma immune responses may be limited by low MHC class I exonic mutation frequency. Therefore, we modelled human neuroblastoma T‐cell deficient...

10.1002/ijc.31532 article EN International Journal of Cancer 2018-04-17

To determine return to running criteria currently used by physiotherapists following anterior cruciate ligament (ACL) injury. Self-reported online international survey. An survey of across Australia, the Netherlands and France.. A total 476 respondants participated in Australia (n = 153), 162), France 161). For a non-operative approach, majority respondents chose swelling (40.55%, n 193/476), pain (38.24%, 182/476), knee extensor strength (34.34%, 163/476), single leg squat (31.93%, 152/476)...

10.1016/j.ptsp.2024.02.005 article EN cc-by Physical Therapy in Sport 2024-03-01

Abstract: Background: Recent work has indicated a role for anti‐Gal α 1‐3Gal (Gal) and anti‐non‐Gal xenoantibodies in the primate humoral rejection response against human‐decay accelerating factor (hDAF) transgenic pig organs. Our laboratory shown that anti‐porcine xenograft antibodies humans non‐human primates are encoded by small number of germline IgV H progenitors. In this study, we extended our analysis to identify genes encoding immunosuppressed cynomolgus monkeys ( Macaca fascicularis...

10.1111/j.1399-3089.2007.00381.x article EN Xenotransplantation 2007-03-01

Complications subsequent to repair of a congenital tracheoesophageal fistula (TEF) with esophageal atresia (EA) include leak at the anastomosis, stricture formation, and recurrent fistula. Recurrence is uncommon, optimal management for debatable. As many symptoms TEF recurrence are similar common postoperative sequelae, diagnosis these recurrences can be quite challenging. We report case 12 year old patient history Type B EA/TEF (proximal pouch fistula, distal atresia) who was discovered...

10.1016/j.epsc.2017.11.016 article EN cc-by-nc-nd Journal of Pediatric Surgery Case Reports 2017-11-23

Abstract Introduction: Despite aggressive medical and surgical therapy, the 5-year survival rate for high-risk neuroblastoma remains poor at 40-50%. The vast majority of these deaths are not due to primary tumor but from recurrent metastatic disease. However, current in vivo models primarily study efficacy novel treatments on growth (subcutaneous, orthotopic, transgenic) as opposed residual disease seen patients. We sought create an model minimal (MRD), which clinically replicates recurrence...

10.1158/1538-7445.pedca15-a05 article EN Cancer Research 2016-03-01
Coming Soon ...